Why Is Compass Therapeutics (CMPX) Stock Down -29.40% Today?
Key Takeaways
- Shares plunged roughly 29.4% in Tuesday's session, tumbling to about $1.29 after closing at $1.82 the prior trading day.
- Primary catalyst: The U.S. Food and Drug Administration (FDA) recommended that the company run an additional trial before submitting a marketing application for its lead drug, tovecimig.
- Secondary driver: The setback casts doubt on the near-term regulatory timeline for a Biologics License Application (BLA) that the company had expected to file later this year.
- Context: The stock had already fallen more than 60% year-to-date amid a prolonged slide in small- and mid-cap clinical-stage biotech names.
- What traders are watching next: The company's ongoing engagement with the FDA and any clarity on a revised regulatory path for tovecimig.
Opening Summary
CMPX, the stock of Compass Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company developing antibody-based cancer therapies, fell sharply on Tuesday. The shares were trading around $1.29 in the latest session, down approximately 29.4% from the previous close of $1.82. The selloff followed the company's disclosure that the FDA has recommended it conduct an additional trial to demonstrate a survival benefit for tovecimig before submitting a marketing application.
FDA Feedback on Tovecimig Drives the Decline
The move was fundamentally regulatory news rather than a broad-market event. Compass Therapeutics said that, citing feedback from a recent meeting with the regulator, the FDA recommended the company run a new trial to show the survival benefit of tovecimig prior to filing a BLA. The drug, a bispecific antibody targeting DLL4 and VEGF-A, is being developed for patients with advanced biliary tract cancer (BTC), a rare and aggressive malignancy affecting the bile ducts and gallbladder.
The company pushed back on the recommendation, stating it does not believe a new trial is warranted before a BLA submission based on data from its Phase 2/3 COMPANION-002 study and the urgent unmet medical need in BTC. Compass said it intends to continue engaging with the FDA as it weighs its regulatory options.
Why the FDA's Stance Matters
The regulatory guidance strikes at the heart of the investment thesis for CMPX. Tovecimig is the company's lead asset, and a timely BLA submission had been a central near-term catalyst for the stock. Requiring an additional trial would likely push out any potential approval timeline, raise development costs, and extend the period before the company could generate revenue from the therapy.
In the COMPANION-002 study, tovecimig combined with paclitaxel delivered an objective response rate (ORR) of 18%, versus 5.3% for paclitaxel alone, and a median progression-free survival of 4.7 months, compared with 2.6 months. However, the company acknowledged that the overall survival analyses did not reach statistical significance — a key consideration behind the FDA's request for further evidence of survival benefit.
Market Context and Trading Activity
The selloff was consistent with the reaction seen in premarket trading, where shares initially dropped by roughly 40% before paring some losses during the regular session. The decline was accompanied by elevated trading volume relative to the stock's recent averages, reflecting heavy repositioning by investors who had positioned for a smoother regulatory path.
The move was largely company-specific rather than driven by sector momentum. While biotechnology and small-cap healthcare names have faced a challenging year, the magnitude of Tuesday's drop for CMPX diverged sharply from the broader market and from most peers, underscoring that the FDA update — not general sentiment — was the dominant force. From a technical standpoint, the stock broke decisively below its recent consolidation range and its prior session lows, leaving it near the lower end of its 52-week trading band.
What Comes Next for CMPX
The outlook for CMPX now hinges on the outcome of the company's continued dialogue with the FDA. Investors will watch for any signal that the regulator's position could soften, whether the company pursues a revised filing strategy, or whether it ultimately commits to the additional trial the FDA has recommended. The company has previously indicated that its cash and marketable securities are expected to fund operations into 2028, which provides some financial runway but does not eliminate the strategic uncertainty.
Key upcoming considerations include the company's next quarterly earnings report and any further corporate or regulatory updates on tovecimig. Analysts have broadly maintained constructive long-term views on the shares, but the FDA's recommendation introduces meaningful risk around the timing and viability of the lead program. As with any clinical-stage biotech, the path forward carries substantial uncertainty, and investors should weigh the regulatory, clinical, and financing risks carefully.
Trending AI Robots
For traders seeking a systematic approach to market moves like this, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore different approaches to navigating volatile market environments. Visit the Trending AI Robots page to review the current lineup of top-performing bots.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CMPX in downward trend: price dove below 50-day moving average on September 08, 2026
CMPX moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend. In 30 of 31 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMPX as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CMPX turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The 10-day moving average for CMPX crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CMPX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMPX advanced for three days, in 233 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CMPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 174 of 198 cases where CMPX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.061) is normal, around the industry mean (25.951). P/E Ratio (0.000) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (555.556) is also within normal values, averaging (436.793).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CMPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement